Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 65, Issue , 2016, Pages 269-287

  Van Skike, C E ^a   Maggio, S E ^a   Reynolds, A R ^a   Casey, E M ^a   Bardo, M T ^a,b   Dwoskin, L P ^a   Prendergast, M A ^a,b   Nixon, K ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alcohol; Alcoholism; Nicotine; Pharmacotherapy; Polysubstance abuse; Smoking

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; AMPA RECEPTOR; ANTICONVULSIVE AGENT; DISULFIRAM; DOPAMINE; ENDOCANNABINOID; GSK 598809; KAINIC ACID RECEPTOR; MECAMYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE VACCINE; NICOTINIC RECEPTOR; OPIATE ANTAGONIST; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VARENICLINE; DRUGS USED IN THE TREATMENT OF ADDICTION; NICOTINE GUM;

ALCOHOL ABSTINENCE; ALCOHOL USE DISORDER; ALCOHOLISM; ARTICLE; COGNITION; COMORBIDITY; DRUG MECHANISM; HUMAN; MULTIPLE DRUG ABUSE; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; SIGNAL TRANSDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE; ALCOHOL-RELATED DISORDERS; ANIMAL; COMPLICATION; DRUG DEVELOPMENT; DRUG INTERACTION; METABOLISM; TOBACCO USE DISORDER;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; ANIMALS; COMORBIDITY; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 84949530948     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.11.004     Document Type: Article

References (391)

1. Addolorato G., Caputo F., Capristo E., Domenicali M., Bernardi M., Janiri L., Agabio R., Colombo G., Gessa G.L., Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002, 37:504-508.
2. Addolorato G., Leggio L., Ferrulli A., Cardone S., Bedogni G., Caputo F., Gasbarrini G., Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011, 46:312-317.
3. Agabio R., Maccioni P., Carai M.A., Gessa G.L., Froestl W., Colombo G. The development of medications for alcohol-use disorders targeting the GABAB receptor system. Recent Pat. CNS Drug Discov. 2012, 7:113-128.
4. Agaku I.T., King B.A., Dube S.R. Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb. Mortal. Wkly Rep. 2014, 63:29-34.
5. Aistrup G.L., Marszalec W., Narahashi T. Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. Mol. Pharmacol. 1999, 55:39-49.
6. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005, 40:147-150.
7. Anton R.F., Kranzler H., Breder C., Marcus R.N., Carson W.H., Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2008, 28:5-12.
8. Anton R.F., Myrick H., Baros A.M., Latham P.K., Randall P.K., Wright T.M., Stewart S.H., Waid R., Malcolm R. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J. Clin. Psychopharmacol. 2009, 29:334-342.
9. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A., Group, C.S.R. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
10. Arcioni R., della Rocca M., Romano S., Romano R., Pietropaoli P., Gasparetto A. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth. Analg. 2002, 94:1553-1557. (table of contents).
11. Arias A.J., Feinn R., Oncken C., Covault J., Kranzler H.R. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2010, 30:318-322.
12. Augier E., Vouillac C., Ahmed S.H. Diazepam promotes choice of abstinence in cocaine self-administering rats. Addict. Biol. 2012, 17:378-391.
13. Balfour D.J. Neural mechanisms underlying nicotine dependence. Addiction 1994, 89:1419-1423.
14. Baltieri D.A., Daro F.R., Ribeiro P.L., de Andrade A.G. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103:2035-2044.
15. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol. 1998, 12:37-67.
16. 35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Brain Res. 1999, 815:89-97.
17. Batel P., Pessione F., Maitre C., Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 1995, 90:977-980.
18. Belcheva M.M., Barg J., McHale R.J., Gao X.M., Chuang D.M., Coscia C.J. Up-regulation of delta opioid receptors in neuroblastoma hybrid cells: evidence for differences in the mechanisms of action of sodium butyrate and naltrexone. J. Pharmacol. Exp. Ther. 1991, 259:302-309.
19. Bell R.L., Eiler B.J., Cook J.B., Rahman S. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 2009, 43:581-592.
20. Bell R.L., Rodd Z.A., Lumeng L., Murphy J.M., McBride W.J. The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict. Biol. 2006, 11:270-288.
21. Bender S., Scherbaum N., Soyka M., Ruther E., Mann K., Gastpar M. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int. J. Neuropsychopharmacol. 2007, 10:653-660.
22. Benwell M.E., Balfour D.J. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmacol. 1992, 105:849-856.
23. Biala G., Budzynska B. Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol. Pharmacol. Rep. 2010, 62:797-807.
24. Bito-Onon J.J., Simms J.A., Chatterjee S., Holgate J., Bartlett S.E. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict. Biol. 2011, 16:440-449.
25. Blomqvist O., Engel J.A., Nissbrandt H., Soderpalm B. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur. J. Pharmacol. 1993, 249:207-213.
26. Blomqvist O., Ericson M., Engel J.A., Soderpalm B. Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur. J. Pharmacol. 1997, 334:149-156.
27. Booker T.K., Collins A.C. Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions. Alcohol 1997, 14:131-140.
28. Braestrup C., Sanchez C. Escitalopram: a unique mechanism of action. Int. J. Psychiatry Clin. Pract. 2004, 8(Suppl. 1):11-13.
29. Brodie M.S., Pesold C., Appel S.B. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol. Clin. Exp. Res. 1999, 23:1848-1852.
30. Brodie M.S., Shefner S.A., Dunwiddie T.V. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res. 1990, 508:65-69.
31. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., Jou J., Allen V., Tiongson E., Chefer S.I., Koren A.O., Mukhin A.G. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch. Gen. Psychiatry 2006, 63:907-915.
32. Brody A.L., Mukhin A.G., Mamoun M.S., Luu T., Neary M., Liang L., Shieh J., Sugar C.A., Rose J.E., Mandelkern M.A. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry 2014, 71:797-805.
33. Browning K.N., Travagli R.A. Mechanism of action of baclofen in rat dorsal motor nucleus of the vagus. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G1106-G1113.
34. Butler T.R., Prendergast M.A. Neuroadaptations in adenosine receptor signaling following long-term ethanol exposure and withdrawal. Alcohol. Clin. Exp. Res. 2012, 36:4-13.
35. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
36. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2011.
37. Campbell V.C., Taylor R.E., Tizabi Y. Antinociceptive effects of alcohol and nicotine: involvement of the opioid system. Brain Res. 2006, 1097:71-77.
38. Campbell V.C., Taylor R.E., Tizabi Y. Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception. Alcohol. Clin. Exp. Res. 2007, 31:1435-1440.
39. Caprioli D., Celentano M., Dubla A., Lucantonio F., Nencini P., Badiani A. Ambience and drug choice: cocaine- and heroin-taking as a function of environmental context in humans and rats. Biol. Psychiatry 2009, 65:893-899.
40. Carbonnelle E., Sparatore F., Canu-Boido C., Salvagno C., Baldani-Guerra B., Terstappen G., Zwart R., Vijverberg H., Clementi F., Gotti C. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur. J. Pharmacol. 2003, 471:85-96.
41. Carmody T.P., Brischetto C.S., Matarazzo J.D., O'Donnell R.P., Connor W.E. Co-occurrent use of cigarettes, alcohol, and coffee in healthy, community-living men and women. Health Psychol. 1985, 4:323-335.
42. Carpenter-Hyland E.P., Woodward J.J., Chandler L.J. Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. J. Neurosci. 2004, 24:7859-7868.
43. Carroll F.I., Blough B.E., Mascarella S.W., Navarro H.A., Lukas R.J., Damaj M.I. Bupropion and bupropion analogs as treatments for CNS disorders. Adv. Pharmacol. 2014, 69:177-216.
44. Castane A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
45. Champtiaux N., Gotti C., Cordero-Erausquin M., David D.J., Przybylski C., Lena C., Clementi F., Moretti M., Rossi F.M., Le Novere N., McIntosh J.M., Gardier A.M., Changeux J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 2003, 23:7820-7829.
46. Champtiaux N., Han Z.Y., Bessis A., Rossi F.M., Zoli M., Marubio L., McI ntosh J.M., Changeux J.P. Distribution and pharmacology of alpha6 containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. 2002, 22:1208-1217.
47. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 2010, 11:389-401.
48. Chatterjee S., Bartlett S.E. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol. Disord. Drug Targets 2010, 9:60-76.
49. Chatterjee S., Steensland P., Simms J.A., Holgate J., Hurst R.S., Shaffer C.L., Lowe J., Rollema H., Bartlett S.E. Partial agonists of the alpha3beta4 neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 2011, 36:603-615.
50. Cheer J.F., Wassum K.M., Sombers L.A., Heien M.L., Ariansen J.L., Aragona B.J., Wightman R.M. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J. Neurosci. 2007, 27:791-795.
51. Chiappetta V., Garcia-Rodriguez O., Jin C.J., Secades-Villa R., Blanco C. Predictors of quit attempts and successful quit attempts among individuals with alcohol use disorders in a nationally representative sample. Drug Alcohol Depend. 2014, 141:138-144.
52. Chick J., Aschauer H., Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. 2004, 74:61-70.
53. Choi D.W. Excitotoxic cell death. J. Neurobiol. 1992, 23:1261-1276.
54. Cippitelli A., Bilbao A., Hansson A.C., del Arco I., Sommer W., Heilig M., Massi M., Bermúdez-Silva F.J., Navarro M., Ciccocioppo R., de Fonseca F.R., European TARGALC Consortium Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur. J. Neurosci. 2005, 21:2243-2251.
55. Clinicaltrials.gov (December 10 2009a). Effects of the D3 antagonist GSK598809 on food reward and reinforcement. (Retrieved from ). https://clinicaltrials.gov/ct2/show/NCT01039454.
56. Clinicaltrials.gov (February 3 2009b). NicVAX/placebo as an aid for smoking cessation. (Retrieved from ). https://clinicaltrials.gov/ct2/show/NCT00836199?term=nicvax&rank=1.
57. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48:3474-3477.
58. Cohen S.L. Effects of d-amphetamine on responding under second-order schedules of reinforcement with paired and nonpaired brief stimuli. J. Exp. Anal. Behav. 1991, 56:289-302.
59. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 2002, 13:451-463.
60. Cools R., Nakamura K., Daw N.D. Serotonin and dopamine: unifying affective, activational, and decision functions. Neuropsychopharmacology 2011, 36:98-113.
61. Corrigall W.A., Coen K.M. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 1991, 104:167-170.
62. Cosgrove K.P., Esterlis I., Mason G.F., Bois F., O'Malley S.S., Krystal J.H. Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence. Neuropharmacology 2011, 60:1318-1325.
63. Cosgrove K.P., McKay R., Esterlis I., Kloczynski T., Perkins E., Bois F., Pittman B., Lancaster J., Glahn D.C., O'Malley S., Carson R.E., Krystal J.H. Tobacco smoking interferes with GABAA receptor neuroadaptations during prolonged alcohol withdrawal. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:18031-18036.
64. Crabbe J.C., Metten P., Rhodes J.S., Yu C.H., Brown L.L., Phillips T.J., Finn D.A. A line of mice selected for high blood ethanol concentrations shows drinking in the dark to intoxication. Biol. Psychiatry 2009, 65:662-670.
65. Croissant B., Diehl A., Klein O., Zambrano S., Nakovics H., Heinz A., Mann K. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2006, 30:630-635.
66. Crooks P.A., Bardo M.T., Dwoskin L.P. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv. Pharmacol. 2014, 69:513-551.
67. Cui C., Noronha A., Morikawa H., Alvarez V.A., Stuber G.D., Szumlinski K.K., Kash T.L., Roberto M., Wilcox M.V. New insights on neurobiological mechanisms underlying alcohol addiction. Neuropharmacology 2013, 67:223-232.
68. Cui W.Y., Seneviratne C., Gu J., Li M.D. Genetics of GABAergic signaling in nicotine and alcohol dependence. Hum. Genet. 2012, 131:843-855.
69. Czachowski C.L., Samson H.H., Denning C.E. Independent ethanol- and sucrose-maintained responding on a multiple schedule of reinforcement. Alcohol. Clin. Exp. Res. 1999, 23:398-403.
70. Damaj M.I., Carroll F.I., Eaton J.B., Navarro H.A., Blough B.E., Mirza S., Lukas R.J., Martin B.R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 2004, 66:675-682.
71. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
72. Daniely Y., Reich D., Megiddo D., Manor I. P.1.c.055 Metadoxine:a novel 5HT-2B receptor antagonist with a possible therapeutic role in treating ADHD. Eur. Neuropsychopharmacol. 2011, 21:S284-S285.
73. Dave J.R., Eiden L.E., Karanian J.W., Eskay R.L. Ethanol exposure decreases pituitary corticotropin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis, and plasma beta-endorphin levels in the rat. Endocrinology 1986, 118:280-286.
74. David S.P., Lancaster T., Stead L.F., Evins A.E., Prochaska J.J. Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. 2013, 6.
75. De Bejczy A., Lof E., Walther L., Guterstam J., Hammarberg A., Asanovska G., Frank J., Isaksson A., Soderpalm B. Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol. Clin. Exp. Res. 2015, 39:2189-2199.
76. De Biasi M., Dani J.A. Reward, addiction, withdrawal to nicotine. Annu. Rev. Neurosci. 2011, 34:105-130.
77. De Leon J., Rendon D.M., Baca-Garcia E., Aizpuru F., Gonzalez-Pinto A., Anitua C., Diaz F.J. Association between smoking and alcohol use in the general population: stable and unstable odds ratios across two years in two different countries. Alcohol Alcohol. 2007, 42:252-257.
78. De Sousa A.A., De Sousa J., Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J. Subst. Abus. Treat. 2008, 34:460-463.
79. Deehan G.A., Hauser S.R., Waeiss R.A., Knight C.P., Toalston J.E., Truitt W.A., McBride W.J., Rodd Z.A. Co-administration of ethanol and nicotine: the enduring alterations in the rewarding properties of nicotine and glutamate activity within the mesocorticolimbic system of female alcohol-preferring (P) rats. Psychopharmacology 2015, 232:4293-4302.
80. DeNoble V.J., Mele P.C. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology 2006, 184:266-272.
81. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
82. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393:295-314.
83. Di Chiara G., Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann. N. Y. Acad. Sci. 1986, 473:367-381.
84. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. 1988, 85:5274-5278.
85. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., Acquas E., Carboni E., Valentini V., Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004, 47(Suppl. 1):227-241.
86. Diana M., Rossetti Z.I., Gessa G. Rewarding and aversive effects of ethanol: interplay of GABA, glutamate and dopamine. Alcohol Alcohol. 1993, 2:315-319.
87. DiFranza J.R., Guerrera M.P. Alcoholism and smoking. J. Stud. Alcohol 1990, 51:130-135.
88. Dopico A.M., Lovinger D.M. Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol. Rev. 2009, 61:98-114.
89. Doyon W.M., Dong Y., Ostroumov A., Thomas A.M., Zhang T.A., Dani J.A. Nicotine decreases ethanol-induced dopamine signaling and increases self-administration via stress hormones. Neuron 2013, 79:530-540.
90. Doyon W.M., Thomas A.M., Ostroumov A., Dong Y., Dani J.A. Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system. Biochem. Pharmacol. 2013.
91. Doyon W.M., York J.L., Diaz L.M., Samson H.H., Czachowski C.L., Gonzales R.A. Dopamine activity in the nucleus accumbens during consummatory phases of oral ethanol self-administration. Alcohol. Clin. Exp. Res. 2003, 27:1573-1582.
92. Drews E., Zimmer A. Modulation of alcohol and nicotine responses through the endogenous opioid system. Prog. Neurobiol. 2010, 90:1-15.
93. Dwoskin L.P., Rauhut A.S., King-Pospisil K.A., Bardo M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006, 12:178-207.
94. Engle S.E., McIntosh J.M., Drenan R.M. Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via alpha6-containing nicotinic receptors. Neuropharmacology 2015, 91:13-22.
95. Ericson M., Blomqvist O., Engel J.A., Soderpalm B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur. J. Pharmacol. 1998, 358:189-196.
96. Ericson M., Lof E., Stomberg R., Chau P., Soderpalm B. Nicotinic acetylcholine receptors in the anterior, but not posterior, ventral tegmental area mediate ethanol-induced elevation of accumbal dopamine levels. J. Pharmacol. Exp. Ther. 2008, 326:76-82.
97. Ericson M., Lof E., Stromberg R., Soderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J. Pharmacol. Exp. Ther. 2009, 32:225-230.
98. Erwin B.L., Slaton R.M. Varenicline in the treatment of alcohol use disorders. Ann. Pharmacother. 2014, 48:1445-1455.
99. Exley R., Maubourguet N., David V., Eddine R., Evrard A., Pons S., Marti F., Threlfell S., Cazala P., McIntosh J.M., Changeux J.P., Maskos U., Cragg S.J., Faure P. Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc. Natl. Acad. Sci. 2011, 108:7577-7582.
100. Faden A.I., Sacksen I., Noble L.J. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism. J. Pharmacol. Exp. Ther. 1988, 245:742-748.
101. Falk D.E., Castle I.J., Ryan M., Fertig J., Litten R.Z. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J. Addict. Med. 2015, 9:296-303.
102. Falk D.E., Yi H.Y., Hiller-Sturmhofel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Res. Health 2006, 29:162-171.
103. Farook J.M., Lewis B., Gaddis J.G., Littleton J.M., Barron S. Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology 2009, 83:379-384.
104. Feduccia A.A., Simms J.A., Mill D., Yi H.Y., Bartlett S.E. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. Br. J. Pharmacol. 2014, 171:3420-3431.
105. Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J. Neurosci. 1997, 17:5747-5759.
106. Ferguson S.G., Shiffman S., Gwaltney C.J. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J. Consult. Clin. Psychol. 2006, 74:1153-1161.
107. Fernandez Miranda J.J., Marina Gonzalez P.A., Montes Perez M., Diaz Gonzalez T., Gutierrez Cienfuegos E., Antuna Diaz M.J., Bobes Garcia J. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12month follow-up study. Actas Esp. Psiquiatr. 2007, 35:236-242.
108. Fields H.I., Hjelmstad G.O., Margolis E.B., Nicola S.M. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu. Rev. Neurosci. 2007, 30:289-316.
109. Fiore M.C., Jaen C.R., Baker T.B., Vailey W.C., Benowitz N.L., Curry S.J. Treating tobacco use and dependence: 2008 update. Clinical Practice Guidelines 2008, US Department of Health and Human Services, PHS, Rockville MD, (2008).
110. Flatscher-Bader T., Zuvela N., Landis N., Wilce P.A. Smoking and alcoholism target genes associated with plasticity and glutamate transmission in the human ventral tegmental area. Hum. Mol. Genet. 2008, 17(1):38-51.
111. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 2003, 6:968-973.
112. Florez G., Garcia-Portilla P., Alvarez S., Saiz P.A., Nogueiras L., Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2008, 32:1251-1259.
113. Florez G., Saiz P.A., Garcia-Portilla P., Alvarez S., Nogueiras L., Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur. Addict. Res. 2011, 17:29-36.
114. Floyd D.W., Jung K.Y., McCool B.A. Chronic ethanol ingestion facilitates N-methyl-d-aspartate receptor function and expression in rat lateral/basolateral amygdala neurons. J. Pharmacol. Exp. Ther. 2003, 307:1020-1029.
115. Foddai M., Dosia G., Spiga S., Diana M. Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 2004, 29:530-536.
116. Ford M.M., McCracken A.D., Davis N.L., Ryabinin A.E., Grant K.A. Discrimination of ethanol-nicotine drug mixtures in mice: dual interactive mechanisms of overshadowing and potentiation. Psychopharmacology 2012, 224:537-548.
117. Forman S.A., Zhou Q. Novel modulation of a nicotinic receptor channel mutant reveals that the open state is stabilized by ethanol. Mol. Pharmacol. 1999, 55:102-108.
118. Franck J., Jayaram-Lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. Curr. Opin. Neurobiol. 2013, 23:692-699.
119. Freedland C.S., Sharpe A.L., Samson H.H., Porrino L.J. Effects of SR141716A on ethanol and sucrose self-administration. Alcohol. Clin. Exp. Res. 2001, 25:277-282.
120. Freund T.F., Hajos N. Excitement reduces inhibition via endocannabinoids. Neuron 2003, 38:362-365.
121. Fucito L.M., Toll B.A., Wu R., Romano D.M., Tek E., O'Maley S.S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011, 215:655-663.
122. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I., et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986, 256:1449-1455.
123. Funk D., Lo S., Coen K., Le A.D. Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse. Behav. Brain Res. 2015, 296:157-162.
124. Furieri F.A., Nakamura-Palacios E.M. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2007, 68:1691-1700.
125. Gallego X., Ruiz-Medina J., Valverde O., Molas S., Robles N., Sabria J., Crabbe J.C., Dierssen M. Transgenic over expression of nicotinic receptor alpha 5, alpha 3, and beta 4 subunit genes reduces ethanol intake in mice. Alcohol 2012, 46:205-215.
126. Gamaleddin I.H., Trigo J.M., Gueye A.B., Zvonok A., Makriyannis A., Goldberg S.R., Le Foll B. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front. Psychiatry 2015, 6:41.
127. Garbutt J.C. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr. Pharm. Des. 2010, 16:2091-2097.
128. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., Loewy J.W., Ehrich E.W., Vivitrex Study, G. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
129. Geisler S., Zahm D.S. Afferents of the ventral tegmental area in the rat anatomical substratum for integrative functions. J. Comp. Neurol. 2005, 490:270-294.
130. Gessa G.L., Muntoni F., Collu M., Vargiu L., Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 1985, 348:201-203.
131. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol. 1996, 31(Suppl. 1):33-42.
132. Ginsburg B.C., Lamb R.J. Effects of chronic fluvoxamine on ethanol- and food-maintained behaviors. Life Sci. 2006, 79:1228-1233.
133. Ginsburg B.C., Koek W., Javors M.A., Lamb R.J. Effects of fluvoxamine on a multiple schedule of ethanol- and food-maintained behavior in two rat strains. Psychopharmacology 2005, 180:249-257.
134. Gonzales R.A., Job M.O., Doyon W.M. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol. Ther. 2004, 103:121-146.
135. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
136. Gonzalez S., Cascio M.G., Fernandez-Ruiz J., Fezza F., Di Marzo V., Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002, 954:73-81.
137. Gotti C., Cuiducci S., Tedesco V., Corbioli S., Zanetti I., Moretti M., Zanardi A., Rimondini R., Mugnaini M., Clementi F., Chiamulera C., Zoli M. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating the systemic nicotine effects on dopamine release, locomotion and reinforcement. J. Neurosci. 2010, 30:5311-5325.
138. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 2006, 27:482-491.
139. Grady S.R., Drennan R.M., Breining S.R., Yohannes D., Wageman C.R., Fedorov N.B., McKinney S., Whiteaker P., Bencherif M., Lester H.A., Marks M.J. Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*, α6β2*, α3β4* and α7-nicotine acetylcholine receptors. Neuropharmacology 2010, 58:10-66.
140. Grady S.R., Salminen O., Laverty D.C., Whiteaker P., McIntosh J.M., Collins A.C., Marks M.J. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem. Pharmacol. 2007, 74:1235-1246.
141. Grant B.F., Goldstein R.B., Saha T.D., Chou S.P., Jung J., Zhang H., Pickering R.P., Ruan W.J., Smith S.M., Huang B., Hasin D.S. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015, 72:757-766.
142. Grant K.A., Valverius P., Hudspith M., Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur. J. Pharmacol. 1990, 176:289-296.
143. Griffiths R.R., Wurster R.M., Brady J.V. Choice between food and heroin: effects of morphine, naloxone, and secobarbital. J. Exp. Anal. Behav. 1981, 35:335-351.
144. Grobin A.C., Matthews D.B., Devaud L.L., Morrow A.L. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998, 139:2-19.
145. Gual A., He Y., Torup L., van den Brink W., Mann K. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur. Neuropsychopharmacol. 2013, 23:1432-1442.
146. Guardia J., Segura L., Gonzalvo B., Iglesias L., Roncero C., Cardus M., Casas M. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol. Clin. Exp. Res. 2004, 28:736-745.
147. Guerrini I., Gentili C., Nelli G., Guazzelli M. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst. Abuse Treat. Prev. Policy 2006, 1:35.
148. Han Y. Nicotine, an anti-inflammation molecule. Inflamm. Cell. Signal. 2014, 1. 10.14800/ics.14155.
149. Hansson A.C., Bermudez-Silva F.J., Malinen H., Hyytia P., Sanchez-Vera I., Rimondini R., Rodriguez de Fonseca F., Kunos G., Sommer W.H., Heilig M. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 2007, 32:117-126.
150. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., Fu M.C., Hart S.R., Pedigo N.W., Littleton J.M. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. 2002, 26:1779-1793.
151. Harrison E.L., McKee S.A. Young adult non-daily smokers: patterns of alcohol and cigarette use. Addict. Behav. 2008, 33:668-674.
152. Harrison E.L., Hinson R.E., McKee S.A. Experimenting and daily smokers: episodic patterns of alcohol and cigarette use. Addict. Behav. 2009, 34:484-486.
153. Hauser S.R., Katner S.N., Deehan G.A., Ding Z.M., Toalston J.E., Scott B.J., Bell R.L., McBride W.J., Rodd Z.A. Development of an oral operant nicotine/ethanol co-use model in alcohol-preferring (p) rats. Alcohol. Clin. Exp. Res. 2012, 36:1963-1972.
154. Hendrickson L.M., Gardner P., Tapper A.R. Nicotinic acetylcholine receptors containing the alpha4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption. Channels (Austin) 2011, 5:124-127.
155. Hendrickson L.M., Guilford M.J., Tapper A.R. Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front. Psychiatry 2013, 4:1-16.
156. Hendrickson L.M., Zhao-Shea R., Pang X., Gardner P.D., Tapper A.R. Activation of alpha4 nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J. Neurosci. 2010, 30:10169-10176.
157. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1932-1936.
158. Herve D., Pickel V.M., Joh T.H., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 1987, 435:71-83.
159. Hillard C.J., Weinlander K.M., Stuhr K.L. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012, 204:207-229.
160. Homberg J.R., Lesch K.P. Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 2011, 69(6):513-519.
161. Hungund B.L., Basavarajappa B.S. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. Ann. N. Y. Acad. Sci. 2004, 1025:515-527.
162. Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem. 2003, 84:698-704.
163. Hurley L., Taylor R., Tizabi Y. Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox. Res. 2012, 21:57-69.
164. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., Khayrallah M.A., Schroeder D.R., Glover P.N., Sullivan C.R., Croghan I.T., Sullivan P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997, 337:1195-1202.
165. Hutto C.W., Crowder W.F. Dosage choices of rats for morphine, for heroin, and between morphine and heroin. Pharmacol. Biochem. Behav. 1997, 58:133-140.
166. Hwa L.S., Chu A., Levinson S.A., Kayyali T.M., DeBold J.F., Miczek K.A. Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcohol. Clin. Exp. Res. 2011, 35:1938-1947.
167. Jerlhag E., Grotli M., Luthman K., Svensson L., Engel J.A. Role of the subunit composition of central nicotinic acetylcholine receptors for the stimulatory and dopamine-enhancing effects of ethanol. Alcohol Alcohol. 2006, 41:486-493.
168. Jhou T.C., Fields H.L., Baxter M.G., Saper C.B., Holland P.C. The rostromedial tegmental nucleus (RMTg), a GABAergic afferent to midbrain dopamine neurons, encodes aversive stimuli and inhibits motor responses. Neuron 2009, 61:786-800.
169. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Ma J.Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry 2004, 61:905-912.
170. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
171. Johnson B.A., Ait-Daoud N., Seneviratne C., Roache J.D., Javors M.A., Wang X.Q., Liu L., Penberthy J.K., DiClemente C.C., Li M.D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 168:265-275.
172. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
173. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
174. Jorgensen C.H., Pedersen B., Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol. Clin. Exp. Res. 2011, 35:1749-1758.
175. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Brain Res. Rev. 1993, 18:75-113.
176. Kamens H.M., Andersen J., Picciotto M.R. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology 2010, 208:613-626.
177. Kaminski B.J., Weerts E.M. The effects of varenicline on alcohol seeking and self-administration in baboons. Alcohol. Clin. Exp. Res. 2014, 38:376-383.
178. Kanny D., Liu Y., Brewer R.D., Lu H., Centers for Disease, C., & Prevention Binge drinking - United States, 2011. MMWR Surveill. Summ. 2013, 62(Suppl. 3):77-80.
179. Karkhanis A.N., Rose J.H., Huggins K.N., Konstantopoulos J.K., Jones S.R. Chronic intermittent ethanol exposure reduces presynaptic dopamine neurotransmission in the mouse nucleus accumbens. Drug Alcohol Depend. 2015, 50:24-30.
180. Kelai S., Renoir T., Chouchana L., Saurini F., Hanoun N., Hamon M., Lanfumey L. Chronic voluntary ethanol intake hypersensitizes 5-HT(1A) autoreceptors in C57BL/6J mice. J. Neurochem. 2008, 107:1660-1670.
181. King A.C., Epstein A.M. Alcohol dose-dependent increases in smoking urge in light smokers. Alcohol. Clin. Exp. Res. 2005, 29:547-552.
182. King A.C., Cao D., O'Malley S.S., Kranzler H.R., Cai X., deWit H., Matthews A.K., Stachoviak R.J. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J. Clin. Psychopharmacol. 2012, 32:630-636.
183. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
184. Koob G.F., Kenneth Lloyd G., Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat. Rev. Drug Discov. 2009, 8:500-515.
185. Koppaka V., Thompson D.C., Chen Y., Ellermann M., Nicolaou K.C., Juvonen R.O., Petersen D., Deitrich R.A., Hurley T.D., Vasiliou V. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev. 2012, 64:520-539.
186. Kosten T., Owens S.M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 2005, 108:76-85.
187. Krampe H., Spies C.D., Ehrenreich H. Supervised disulfiram in the treatment of alcohol use disorder: a commentary. Alcohol. Clin. Exp. Res. 2011, 35:1732-1736.
188. Kranzler H.R., Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am. J. Addict. 2008, 17:70-76.
189. Kranzler H.R., Armeli S., Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol. Clin. Exp. Res. 2012, 36:739-744.
190. Kranzler H.R., Armeli S., Tennen H., Covault J., Feinn R., Arias A.J., Pettinati H., Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J. Clin. Psychopharmacol. 2011, 31:22-30.
191. Kranzler H.R., Pierucci-Lagha A., Feinn R., Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol. Clin. Exp. Res. 2003, 27:1150-1155.
192. Kumar S., Porcu P., Werner D.F., Matthews D.B., Diaz-Granados J.L., Helfand R.S., Morrow A.L. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology 2009, 205:529-564.
193. Kuzmin A., Jerlhag E., Liljequist S., Engel J. Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology 2009, 203:99-108.
194. Kuzniecky R., Hetherington H., Ho S., Pan J., Martin R., Gilliam F., Hugg J., Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 1998, 51:627-629.
195. Lajtha A., Sershen H. Nicotine: alcohol reward interactions. Neurochem. Res. 2010, 35:1248-1258.
196. Larsson A., Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci. Biobehav. Rev. 2004, 27:713-720.
197. Larsson A., Edstrom L., Svensson L., Soderpalm B., Engel J.A. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol. 2005, 40:349-358.
198. Larsson A., Jerlhag E., Svensson L., Soderpalm B., Engel J.A. Is an alpha-conotoxin MII sensitive mechanism involved in the neurochemical, stimulatory and rewarding effects of ethanol?. Alcohol 2004, 34:239-250.
199. Larsson A., Svensson L., Soderpalm B., Engel J.A. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol 2002, 28:157-167.
200. Laviolette S.R., van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nat. Rev. Neurosci. 2004, 5:55-65.
201. Lawrence A.J., Beart P.M., Kalivas P.W. Neuropharmacology of addiction-setting the scene. Br. J. Pharmacol. 2008, 154:259-260.
202. Le A.D., Corrigall W.A., Harding J.W., Juzytsch W., Li T.K. Involvement of nicotinic receptors in alcohol self-administration. Alcohol. Clin. Exp. Res. 2000, 24:155-163.
203. Le A.D., Funk D., Lo S., Coen K. Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse. Psychopharmacology 2014, 231:4019-4029.
204. Le A.D., Li Z., Funk D., Shram M., Li T.K., Shaham Y. Increased vulnerability to nicotine self-administration and relapse in alcohol-naive offspring of rats selectively bred for high alcohol intake. J. Neurosci. 2006, 26:1872-1879.
205. Le A.D., Wang A., Harding S., Juzytsch W., Shaham Y. Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. Psychopharmacology 2003, 168(1-2):216-221.
206. Leao R.M., Cruz F.C., Vendruscolo L.F., de Guglielmo G., Logrip M.L., Planeta C.S., Hope B.T., Koob G.F., George O. Chronic nicotine activates stress/reward-related brain regions and facilitates the transition to compulsive alcohol drinking. J. Neurosci. 2015, 35:6241-6253.
207. Lenoir M., Augier E., Vouillac C., Ahmed S.H. A choice-based screening method for compulsive drug users in rats. Curr. Protoc. Neurosci. 2013, (Chapter 9, Unit 9 44).
208. Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004, 13(Suppl. 1):S5-S9. (discussion S10).
209. Lesouef N., Bellet F., Mounier G., Beyens M.N. Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie 2014, 69:427-435.
210. Lewohl J.M., Wilson W.R., Mayfield R.D., Brozowski S.J., Morrisett R.A., Harris R.A. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat. Neurosci. 1999, 2:1084-1090.
211. Liang J., Cagetti E., Olsen R.W., Spigelman I. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. J. Pharmacol. Exp. Ther. 2004, 310:1234-1245.
212. Liang J., Suryanarayanan A., Abriam A., Snyder B., Olsen R.W., Spigelman I. Mechanisms of reversible GABAA receptor plasticity after ethanol intoxication. J. Neurosci. 2007, 27:12367-12377.
213. Liljequist S., Ahlenius S., Engel J. The effect of chronic ethanol treatment on behaviour and central monoamines in the rat. Naunyn Schmiedeberg's Arch. Pharmacol. 1977, 300:205-216.
214. Lin S.H., Lee L.T., Yang Y.K. Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin. Psychopharmacol. Neurosci. 2014, 12:196-202.
215. Lippai D., Bala S., Csak T., Kurt-Jones E.A., Szabo G. Chronic alcohol-induced microRNA-155 contributes to neuroinflammation in a TLR4-dependent manner in mice. PLoS One 2013, 8.
216. Litten R.Z., Ryan M.L., Falk D.E., Reilly M., Fertig J.B., Koob G.F. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol. Clin. Exp. Res. 2015, 39:579-584.
217. Litten R.Z., Ryan M.L., Fertig J.B., Falk D.E., Johnson B., Dunn K.E., Green A.I., Pettinati H.M., Ciraulo D.A., Sarid-Segal O., Kampman K., Brunette M.F., Strain E.C., Tiouririne N.A., Ransom J., Scott C., Stout R., Group, N.S. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J. Addict. Med. 2013, 7:277-286.
218. Liu L., Hendrickson L.M., Guildford M.J., Zhao-Shea R., Gardner P.D., Tapper A.R. Nicotinic acetylcholine receptors containing the α4 subunit modulate alcohol reward. Biol. Psychiatry 2013, 73:738-746.
219. Lodge D.J., Grace A.A. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proc. Natl. Acad. Sc.i 2006, 103:5167-5172.
220. Lof E., Chau P.P., Stomberg R., Soderpalm B. Ethanol-induced dopamine elevation in the rat - modulatory effects by subchronic treatment with nicotinic drugs. Eur. J. Pharmacol. 2007, 555:139-147.
221. Lopez-Moreno J.A., Gonzalez-Cuevas G., Navarro M. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiol. Dis. 2007, 25:274-283.
222. Lopez-Moreno J.A., Scherma M., Rodriguez de Fonseca F., Gonzalez-Cuevas G., Fratta W., Navarro M. Changed accumbal responsiveness to alcohol in rats pre-treated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neurosci. Lett. 2008, 433:1-5.
223. Lovinger D.M. Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. Alcohol Alcohol. Suppl. 1991, 1:181-185.
224. Lovinger D.M. Excitotoxicity and alcohol-related brain damage. Alcohol. Clin. Exp. Res. 1993, 17(1):19-27.
225. Lovinger D.M., White G., Weight F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989, 243:1721-1724.
226. Ma J.Z., Ait-Daoud N., Johnson B.A. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006, 101:1561-1568.
227. Macenski M.J., Meisch R.A. Ethanol-reinforced responding of naive rhesus monkeys: acquisition without induction procedures. Alcohol 1992, 9:547-554.
228. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 2005, 299-325.
229. Mah S.J., Fleck M.W., Lindsley T.A. Ethanol alters calcium signaling in axonal growth cones. Neuroscience 2011, 189:384-396.
230. Maisel N.C., Blodgett J.C., Wilbourne P.L., Humphreys K., Finney J.W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. Addiction 2013, 108:275-293.
231. Maldonado A.M., Finkbeiner L.M., Alipour K.K., Kirstein C.L. Voluntary ethanol consumption differs in adolescent and adult male rats using a modified sucrose-fading paradigm. Alcohol. Clin. Exp. Res. 2008, 32:1574-1582.
232. Mameli-Engvall M., Evrard A., Pons S., Maskos U., Svensson T.H., Changeux J.P., Faure P. Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron 2006, 50:911-921.
233. Mann K., Bladstrom A., Torup L., Gual A., van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol. Psychiatry 2013, 73:706-713.
234. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res. 2004, 28:51-63.
235. Manzardo A.M., Stein L., Belluzzi J.D. Rats prefer cocaine over nicotine in a two-lever self-administration choice test. Brain Res. 2002, 924:10-19.
236. Marra D., Warot D., Berlin I., Hispard E., Notides C., Tilikete S., Payan C., Lepine J.P., Dally S., Aubin H.J. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol. Clin. Exp. Res. 2002, 26:1545-1552.
237. Marshall C.E., Dadmarz M., Hofford J.M., Gottheil E., Vogel W.H. Self-administration of both ethanol and nicotine in rats. Pharmacology 2003, 67:143-149.
238. Martinez D., Gil R., Slifstein M., Hwang D.R., Huang Y., Perez A., Kegeles L., Talbot P., Evans S., Krystal J., et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 2005, 58:779-786.
239. Maskos U. The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modular of the dopaminergic system: relevance to drugs of abuse and pathology. Br. J. Pharmacol. 2008, 153:5438-5445.
240. Mason B.J., Goodman A.M., Chabac S., Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J. Psychiatr. Res. 2006, 40:383-393.
241. Mason B.J., Quello S., Goodell V., Shadan F., Kyle M., Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern. Med. 2014, 174:70-77.
242. Matson L.M., Grahame N.J. Pharmacologically relevant intake during chronic, free-choice drinking rhythms in selectively bred high alcohol-preferring mice. Addict. Biol. 2013, 18:921-929.
243. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
244. Matsumura N., Nakaki T. Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect. Eur. J. Pharmacol. 2014, 741:237-246.
245. Matthews D.B., Overstreet D.H., Rezvani A.H., Devaud L.L., Morrow A.L. Effects of sweetened ethanol solutions on ethanol self-administration and blood ethanol levels. Pharmacol. Biochem. Behav. 2001, 68:13-21.
246. Maurer P., Bachmann M.F. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin. Investig. Drugs 2007, 16:1775-1783.
247. McBride W.J., Rodd Z.A., Bell R.L., Lumeng L., Li T.K. The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats-animal models of alcoholism. Alcohol 2014, 48:209-215.
248. McKee S.A., Weinberger A.H. How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?. Annu. Rev. Clin. Psychol. 2013, 9:649-674.
249. McKee S.A., Falba T., O'Malley S.S., Sindelar J., O'Connor P.G. Smoking status as a clinical indicator for alcohol misuse in US adults. Arch. Intern. Med. 2007, 167:716-721.
250. McKee S.A., Harrison E.L., O'Malley S.S., Krishnan-Sarin S., Shi J., Tetrault J.M., Picciotto M.R., Petrakis I.L., Estevez N., Balchunas E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry 2009, 66:185-190.
251. McKee S.A., Harrison E.L., Shi J. Alcohol expectancy increases positive responses to cigarettes in young, escalating smokers. Psychopharmacology 2010, 210:355-364.
252. McKee S.A., Hinson R., Rounsaville D., Petrelli P. Survey of subjective effects of smoking while drinking among college students. Nicotine Tob. Res. 2004, 6:111-117.
253. McKee S.A., Young-Wolff K.C., Harrison E.L., Cummings K.M., Borland R., Kahler C.W., et al. Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country Survey. Alcohol. Clin. Exp. Res. 2013, 37:804-810.
254. Meldrum B.S., Chapman A.G. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999, 40(Suppl. 9):S2-S6.
255. Mello N.K., Fivel P.A., Kohut S.J. Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology 2013, 38:1264-1275.
256. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70:801-805.
257. Miller N.S., Gold M.S. Comorbid cigarette and alcohol addiction: epidemiology and treatment. J. Addict. Dis. 1998, 17:55-66.
258. 3H]norepinephrine. J. Pharmacol. Exp. Ther. 2002, 302:1113-1122.
259. Mills E.J., Wu P., Spurden D., Ebbert J.O., Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct. J. 2009, 6:25.
260. Mitchell S.H., de Wit H., Zacny J.P. Effects of varying ethanol dose on cigarette consumption in healthy normal volunteers. Behav. Pharmacol. 1995, 6:359-365.
261. Mitchell J.M., Teague C.H., Kayser A.S., Bartlett S.E., Fields H.L. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 2012, 223:299-306.
262. Morgan D., Sizemore G.M. Animal models of addiction: fat and sugar. Curr. Pharm. Des. 2011, 17:1168-1172.
263. Most D., Workman E., Harris R.A. Synaptic adaptations by alcohol and drugs of abuse: changes in microRNA expression and mRNA regulation. Front. Mol. Neurosci. 2014, 7:85.
264. Mugnaini M., Iavarone L., Cavallini P., Griffante C., Oliosi B., Savoia C., Beaver J., Rabiner E.A., Micheli F., Heidbreder C., Andorn A., Merlo Pich E., Bani M. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013, 38:302-312.
265. Mukhin A.G., Kimes A.S., Chefer S.I., Matochik J.A., Contoreggi C.S., Horti A.G., Vaupel D.B., Pavlova O., Stein E.A. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J. Nucl. Med. 2008, 49:1628-1635.
266. Murail S., Wallner B., Trudell J.R., Bertaccini E., Lindahl E. Microsecond simulations indicate that ethanol binds between subunits and could stabilize an open-state model of a glycine receptor. Biophys. J. 2011, 100:1642-1650.
267. Murphy D.L., Uhl G.R., Holmes A., Ren-Patterson R., Hall F.S., Sora I., Detera-Wadleigh S., Lesch K.P. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav. 2003, 2:350-364.
268. Naassila M., Pierrefiche O., Ledent C., Daoust M. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology 2004, 46:243-253.
269. Nagata K., Aistrup G.I., Huang C.S., Marszalec W., Song J.H., Jeh J.Z., et al. Potent modulation of neuronal nicotinic acetylcholine receptor-channel by ethanol. Neurosci. Lett. 1996, 217:189-193.
270. Narayana P.L., Gupta A.K., Sharma P.K. Use of anti-craving agents in soldiers with alcohol dependence syndrome. Med. J. Armed Forces India 2008, 64:320-324.
271. Narushima M., Uchigashima M., Fukaya M., Matsui M., Manabe T., Hashimoto K., Watanabe M., Kano M. Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J. Neurosci. 2007, 27:496-506.
272. Navarro J.F., Manzaneque J.M. Acute and subchronic effects of tiapride on isolation-induced aggression in male mice. Pharmacol. Biochem. Behav. 1997, 58:255-259.
273. Nickell J.R., Grinevich V.P., Siripurapu K.B., Smith A.M., Dwoskin L.P. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol. Biochem. Behav. 2013, 108:28-43.
274. Nocente R., Vitali M., Balducci G., Enea D., Kranzler H.R., Ceccanti M. Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?. Am. J. Addict. 2013, 22:453-459.
275. Nordberg A., Larsson C., Perdahl E., Winblad B. Cholinergic activity in hippocampus in chronic alcoholism. Drug Alcohol Depend. 1982, 10:333-344.
276. Nutt D.J., Forshall S., Bell C., Rich A., Sandford J., Nash J., Argyropoulos S. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 1999, 9(Suppl. 3):S81-S86.
277. O'Brien C.P., Volpicelli L.A., Volpicelli J.R. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996, 13:35-39.
278. Okamoto T., Harnett M.T., Morikawa H. Hyperpolarization-activated cation current (Ih) is an ethanol target in midbrain dopamine neurons of mice. J. Neurophysiol. 2006, 95:619-626.
279. Olney J.W., Price M.T., Samson L., Labruyere J. The role of specific ions in glutamate neurotoxicity. Neurosci. Lett. 1986, 65:65-71.
280. Omelchenko N., Sesack S.R. Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J. Comp. Neurol. 2005, 483:217-235.
281. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., Anziano R., Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 2006, 166:1571-1577.
282. Ortiz S., Oliva J.M., Perez-Rial S., Palomo T., Manzanares J. Differences in basal cannabinoid CB1 receptor function in selective brain areas and vulnerability to voluntary alcohol consumption in Fawn Hooded and Wistar rats. Alcohol Alcohol. 2004, 39(4):297-302.
283. Ostroumov A., Thomas A.M., Dani J.A., Doyon W.M. Cigarettes and alcohol: the influence of nicotine on operant alcohol self-administration and the mesolimbic dopamine system. Biochem. Pharmacol. 2015, 97:550-557.
284. Paparrigopoulos T., Tzavellas E., Karaiskos D., Kourlaba G., Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry 2011, 11:41.
285. Parsons A.C., Shraim M., Inglis J., Aveyard P., Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst. Rev. 2009.
286. Pava M.J., Woodward J.J. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 2012, 46:185-204.
287. Perkins K.A., Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob. Res. 2008, 10:1245-1250.
288. Perkins K.A., Sexton J.E., DiMarco A., Grobe J.E., Scierka A., Stiller R.L. Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers. Psychopharmacology 1995, 119:205-212.
289. Perrault G., Depoortere R., Morel E., Sanger D.J., Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280:73-82.
290. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., Dackis C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006, 26:610-625.
291. Pettinati H.M., Volpicelli J.R., Luck G., Kranzler H.R., Rukstalis M.R., Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J. Clin. Psychopharmacol. 2001, 21:143-153.
292. Phillips T.J., Reed C. Targeting GABAB receptors for anti-abuse drug discovery. Expert Opin. Drug Discovery 2014, 9:1307-1317.
293. Phillips T.J., Reed C., Pastor R. Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation. Genes Brain Behav. 2015, 14:98-135.
294. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol. 2008, 84:329-342.
295. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
296. Pidoplichko V.I., Noguchi J., Areola O.O., Liang Y., Peterson J., Zhang T., Dani J.A. Nicotinic cholinergic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn. Mem. 2004, 11:60-69.
297. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4(11):873-884.
298. Plebani J.G., Lynch K.G., Rennert L., Pettinati H.M., O'Brien C.P., Kampman K.M. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 2013, 133:754-758.
299. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
300. Prendergast M.A., Mulholland P.J. Glucocorticoid and polyamine interactions in the plasticity of glutamatergic synapses that contribute to ethanol-associated dependence and neuronal injury. Addict. Biol. 2012, 17:209-223.
301. Proctor W.R., Dobelis P., Moritz A.T., Wu P.H. Chronic nicotine treatment differentially modifies acute nicotine an alcohol actions on GABAA and glutamate receptors in hippocampal brain slices. Br. J. Pharmacol. 2011, 162:1351-1363.
302. Rahman S., Prendergast M.A. Cholinergic receptor system as a target for treating alcohol abuse and dependence. Recent Pat. CNS Drug Discov. 2012, 7:145-150.
303. Rahman S., Engleman E.A., Bell R.L. Nicotinic receptor modulation to treat alcohol and drug dependence. Front. Neurosci. 2014, 8:426.
304. Rau K.S., Birdsall E., Hanson J.E., Johnson-Davis K.L., Carroll F.I., Wilkins D.G., Gibb J.W., Hanson G.R., Fleckenstein A.E. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005, 49:820-830.
305. Rauhut A.S., Neugebauer N., Dwoskin L.P., Bardo M.T. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology 2003, 169:1-9.
306. 2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology 2007, 190:241-249.
307. Reus V.I., Obach R.S., Coe J.W., Faessel H., Rollema H., Watsky E., et al. Varenicline: new treatment with efficacy I smoking cessation. Drugs Today 2007, 43:65-75.
308. Reynolds A.R., Berry J.N., Sharrett-Field L., Prendergast M.A. Ethanol withdrawal is required to produce persisting N-methyl-d-aspartate receptor-dependent hippocampal cytotoxicity during chronic intermittent ethanol exposure. Alcohol 2015, 49:219-227.
309. Reynolds A.R., Williams L.A., Saunders M.A., Prendergast M.A. Group 1 mGlu-family proteins promote neuroadaptation to ethanol and withdrawal-associated hippocampal damage. Drug Alcohol Depend. 2015, 156:213-220.
310. Rezvani A.H., Slade S., Wells C., Petro A., Lumeng L., Li T.K., Xiao Y., Brown M.L., Paige M.A., McDowell B.E., Rose J.E., Kellar K.J., Levin E.D. Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology 2010, 211:161-174.
311. Rice M.E., Cragg S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004, 7:583-584.
312. Rinne U.K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989, 39:336-339.
313. Roache J.D., Wang Y., Ait-Daoud N., Johnson B.A. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. Alcohol. Clin. Exp. Res. 2008, 32:1502-1512.
314. Rodd Z.A., Bell R.L., Kuc K.A., Murphy J.M., Lumeng L., McBride W.J. Effects of concurrent access to multiple ethanol concentrations and repeated deprivations on alcohol intake of high-alcohol-drinking (HAD) rats. Addict. Biol. 2009, 14:152-164.
315. Rodd-Henricks Z.A., Bell R.L., Kuc K.A., Murphy J.M., McBride W.J., Lumeng L., Li T.K. Effects of concurrent access to multiple ethanol concentrations and repeated deprivations on alcohol intake of alcohol-preferring rats. Alcohol. Clin. Exp. Res. 2001, 25:1140-1150.
316. Rodriguez de Fonseca F., Roberts A.J., Bilbao A., Koob G.F., Navarro M. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 1999, 20:1109-1114.
317. Roman P.M. Alcohol studies and science: trapped in the velvet cage of medical research? An editorial. J. Stud. Alcohol Drugs Suppl. 2014, 75(Suppl. 17):125-132.
318. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 1994, 56:86-99.
319. Rose J.E., Brauer L.H., Behm F.M., Cramblett M., Calkins K., Lawhon D. Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob. Res. 2004, 6:133-144.
320. Rubio G., Lopez-Munoz F., Ferre F., Martinez-Gras I., Ponce G., Pascual J.M., Jimenez-Arriero M.A., Alamo C. Effects of zonisamide in the treatment of alcohol dependence. Clin. Neuropharmacol. 2010, 33:250-253.
321. Rubio G., Martinez-Gras I., Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2009, 29:584-589.
322. Saija R.K., Rahman S. Nicotinic receptor partial agonists modulate alcohol deprivation effect in C57BL/6J mice. Pharmacol. Biochem. Behav. 2013, 110:161-167.
323. Sajja R.K., Rahman S. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:257-264.
324. Sajja R.K., Rahman S. Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of DeltaFosB in mice. Alcohol 2013, 47:299-307.
325. SAMHSA Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863, Rockville, MD 2014.
326. Samson H.H., Tolliver G.A., Haraguchi M., Hodge C.W. Alcohol self-administration: role of mesolimbic dopamine. Ann. N. Y. Acad. Sci. 1992, 654:242-253.
327. Santos N., Chatterjee S., Henry A., Holgate J., Bartlett S.E. The alpha5 neuronal nicotinic acetylcholine receptor subunit plays an important role in the sedative effects of ethanol but does not modulate consumption in mice. Alcohol. Clin. Exp. Res. 2012, 37:655-662.
328. Schacht J.P., Anton R.F., Randall P.K., Li X., Henderson S., Myrick H. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology 2014, 231:3799-3807.
329. Schilaty N.D., Hedges D.M., Jang E.Y., Folsom R.J., Yorgason J.T., McIntosh J.M., Steffensen S.C. Acute ethanol inhibits dopamine release in the nucleus accumbens via alpha6 nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2014, 349:559-567.
330. Schilstrom B., Rawal N., Mameli-Engvail M., Nomiko G.C., Svensson T.H. Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int. J. Neuropsychopharmacol. 2003, 6:1-11.
331. Schmidt L.G., Kuhn S., Smolka M., Schmidt K., Rommelspacher H. Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002, 26:209-217.
332. Sharma R., Sahota P., Thakkar M.M. Nicotine administration in the cholinergic basal forebrain increases alcohol consumption in C57BL/6J mice. Alcohol. Clin. Exp. Res. 2014, 38:1315-1320.
333. Shytle R.D., Penny E., Silver A.A., Goldman J., Sanberg P.R. Mecamylamine (Inversine): an old antihypertensive with new research directions. J. Hum. Hypertens. 2002, 16:453-457.
334. Sills G.J. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006, 6:108-113.
335. Simms J.A., Steensland P., Medina B., Abernathy K.E., Chandler L.J., Wise R., Bartlett S.E. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol. Clin. Exp. Res. 2008, 32:1816-1823.
336. Simonnet A., Cador M., Caille S. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict. Biol. 2013, 18:930-936.
337. Sinclair J.D., Hyytia P., Nurmi M. The limited access paradigm: description of one method. Alcohol 1992, 9:441-444.
338. Slemmer J.E., Martin B.R., Damaj M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 2000, 295:321-327.
339. Smith B.R., Horan J.T., Gaskin S., Amit Z. Exposure to nicotine enhances acquisition of ethanol drinking by laboratory rats in a limited access paradigm. Psychopharmacology 1999, 142:408-412.
340. Soderpalm B., Ericson M., Olausson P., Blomqvist O., Engel J.A. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav. Brain Res. 2000, 113:85-96.
341. Sotomayor-Zarate R., Gysling K., Busto U.E., Cassels B.K., Tampier L., Quintanilla M.E. Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats. Psychopharmacology 2013, 227:287-298.
342. Sparks J.A., Pauly J.R. Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology 1999, 141:145-153.
343. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51:215-235.
344. Stairs D.J., Neugebauer N.M., Bardo M.T. Nicotine and cocaine self-administration using a multiple schedule of intravenous drug and sucrose reinforcement in rats. Behav. Pharmacol. 2010, 21:182-193.
345. Staley J., Gottschalk C., Petrakis I., Gueorguieva R., O'Malley S., Baldwin R., Jatlow P., Verhoeff N., Perry E., Weinzimmer D., Frohlich E., Ruff E., van Dyck C., Seibyl J., Innis R., Krystal J. Cortical GABAA/benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Arch. Gen. Psychiatry 2005, 62:8787-8888.
346. Stead L.F., Perera R., Bullen C., Mant D., Hartmann-Boyce J., Cahill K., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2012, 11.
347. Steensland P., Simms J.A., Holgate J., Richards J.K., Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12518-12523.
348. Stefani A., Pisani A., De Murtas M., Mercuri N.B., Marciani M.G., Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995, 36:997-1002.
349. Stella L., Addolorato G., Rinaldi B., Capuano A., Berrino L., Rossi F., Maione S. An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol. Res. 2008, 57:312-317.
350. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215(1):89-97.
351. Tabakoff B., Hoffman P.L. The neurobiology of alcohol consumption and alcoholism: an integrative history. Pharmacol. Biochem. Behav. 2013, 113:20-37.
352. Thiele T.E., Marsh D.J., Ste Marie L., Bernstein I.L., Palmiter R.D. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998, 396:366-369.
353. Thomsen M., Fulton B.S., Caine S.B. Acute and chronic effects of the M1/M 4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats. Psychopharmacology 2014, 231:469-479.
354. Tizabi Y., Copeland R.L., Louis V.A., Taylor R.E. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol. Clin. Exp. Res. 2002, 26(3):394-399.
355. Toll B.A., Leary V., Wu R., Salovey P., Meandzija B., O'Malley S.S. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict. Behav. 2008, 33:173-179.
356. Tolliver G.A., Sadeghi K.G., Samson H.H. Ethanol preference following the sucrose-fading initiation procedure. Alcohol 1988, 5:9-13.
357. Torrens M., Fonseca F., Mateu G., Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005, 78(1):1-22.
358. Tsai H.-C., Zhang F., Adamantidis A., Stuber G.D., Bonci A., de Lecea L., Deisseroth K. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science 2009, 324:1080-1084.
359. U.S.Department of Health and Human Services The Health Consequences of Smoking-50Years of Progress: A Report of the Surgeon General 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, (accessed 2015 May 11).
360. van den Brink W., Aubin H.J., Bladstrom A., Torup L., Gual A., Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013, 48:570-578.
361. Vengeliene V., Bilbao A., Molander A., Spanagel R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol. 2008, 154:299-315.
362. Verheul R., Lehert P., Geerlings P.J., Koeter M.W., van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 2005, 178:167-173.
363. Volkow N.D., Skolnick P. New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology 2012, 37:290-292.
364. Volkow N.D., Fowler J.S., Wang G.J., Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol. Learn. Mem. 2002, 78:610-624.
365. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992, 49:876-880.
366. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 1997, 54:737-742.
367. Wang L., Shang S., Kang X., Teng S., Zhu F., Liu B., Wu Q., Li M., Liu W., Xu H., Zhou L., Jiao R., Dou H., Zuo P., Zhang X., Zheng L., Wang S., Wang C., Zhou Z. Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine. Nat. Commun. 2014, 5:3925.
368. Ward S.J., Morgan D., Roberts D.C. Comparison of the reinforcing effects of cocaine and cocaine/heroin combinations under progressive ratio and choice schedules in rats. Neuropsychopharmacology 2005, 30:286-295.
369. Warner C., Shoaib M. How does bupropion work as a smoking cessation aid?. Addict. Biol. 2005, 10:219-231.
370. Weinberger A.H., Pilver C.E., Hoff R.A., Mazure C.M., McKee S.A. Changes in smoking for adults with and without alcohol and drug use disorders: longitudinal evaluation in the US population. Am. J. Drug Alcohol Abuse 2013, 39:186-193.
371. Weiss F., Lorang M.T., Bloom F.E., Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharmacol. Exp. Ther. 1993, 267:250-258.
372. Weissenborn R., Yackey M., Koob G.F., Weiss F. Measures of cocaine-seeking behavior using a multiple schedule of food and drug self-administration in rats. Drug Alcohol Depend. 1995, 38:237-246.
373. Wiesbeck G.A., Weijers H.G., Lesch O.M., Glaser T., Toennes P.J., Boening J. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. 2001, 36:329-334.
374. Wiesbeck G.A., Weijers H.G., Wodarz N., Lesch O.M., Glaser T., Boening J. Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics. Arch. Womens Ment. Health 2003, 6:259-262.
375. Williams S.H. Medications for treating alcohol dependence. Am. Fam. Physician 2005, 72:1775-1780.
376. Wilson M.A., Ricaurte G.A., Molliver M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989, 28:121-137.
377. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94:469-492.
378. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 1989, 40:191-225.
379. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 1990, 11:216-219.
380. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997, 20:92-98.
381. World Health Organization Global status report on alcohol and health 2014 (Accessed March 19, 2015). http://www.who.int/substance:abuse/publications/global_alcohol_report/en/.
382. Wouda J.A., Riga D., De Vries W., Stegeman M., van Mourik Y., Schetters D., Schoffelmeer A.N., Pattij T., De Vries T.J. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology 2011, 216:267-277.
383. Wu G., Tonner P.H., Miller K.W. Ethanol stabilizes the open channel state of the Torpedo nicotinic acetylcholine receptor. Mol. Pharmacol. 1994, 45:102-108.
384. Wu P., Wilson K., Dimoulas P., Mills E.J. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006, 6:300.
385. Wullner U., Gundisch D., Herzog H., Minnerop M., Joe A., Warnecke M., Jessen F., Schutz C., Reinhardt M., Eschner W., Klockgether T., Schmaljohann J. Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci. Lett. 2008, 430:34-37.
386. Xia Y., Driscoll J.R., Wilbrecht L., Margolis E.B., Fields H.L., Hjelmstad G.O. Nucleus accumbens medium spiny neurons target non-dopaminergic neurons in the ventral tegmental area. J. Neurosci. 2011, 31:7811-7816.
387. 3H-nicotinic binding in rat brain. Naunyn Schmiedeberg's Arch. Pharmacol. 1982, 321:74-76.
388. Zhou Y., Kreek M.J. Alcohol: a stimulant activating brain stress responsive systems with persistent neuroadaptation. Neuropharmacology 2014, 87:51-58.
389. Zindel L.R., Kranzler H.R. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J. Stud. Alcohol Drugs Suppl. 2014, 75(Suppl. 17):79-88.
390. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 2002, 22:8785-8789.
391. Zuo Y., Nagata K., Yeh J.Z., Narahashi T. Single-channel analyses of ethanol modulation of neuronal nicotinic acetylcholine receptors. Alcohol. Clin. Exp. Res. 2004, 28:688-696.